Phosphoinositide 3-kinase (putative) (PfPI3K)

Phosphoinositide 3-kinase (putative), specifically the PfPI3K isoform from Plasmodium falciparum, is a critical lipid kinase and a validated drug target for antimalarial therapy. It is responsible for the synthesis of phosphatidylinositol 3-phosphate (PI3P), a key signaling lipid that regulates essential intracellular processes such as vesicular trafficking, endocytosis, and protein sorting within the parasite. PfPI3K is vital for the parasite's survival across multiple life stages, including the asexual blood stage and the liver stage, making it an attractive target for multi-stage antimalarial drugs. The enzyme has gained significant attention as the primary target of the imidazolopiperazine class of antimalarials, most notably Ganaplacide (KAF156), which is currently in advanced clinical trials. Inhibition of PfPI3K disrupts the parasite's ability to process nutrients and export virulence factors, providing a potent mechanism for clearing infections and blocking transmission. However, the potential for resistance due to mutations in the kinase domain remains a significant challenge in the development of long-term therapeutic strategies.

Other names

Phosphatidylinositol 3-kinasePI3KPfPI3KPF3D7_0515300Q8I4U0PI3K_PLAF7

Inhibition of the catalytic activity of the phosphoinositide 3-kinase enzyme, which prevents the conversion of phosphatidylinositol to phosphatidylinositol 3-phosphate (PI3P). This depletion of PI3P disrupts essential intracellular trafficking processes, including the transport of hemoglobin to the food vacuole and the export of proteins to the host cell, leading to parasite death.